The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for February 2011 (PDF).
This issue contains drug safety information on several drugs including dronadarone (Multaq®) and omalizumab (Xolair®).
The anti-arrhythmic dronadarone has been linked with liver toxicity and increased monitoring has been recommended. It is also associated with an increased risk of new onset heart failure and worsening of symptoms of pre-existing heart failure. Patients should be advised to report signs of developing or worsening heart failure such as weight gain, oedema and dyspnoea.
Omalizumab, a sub-cutaneous monoclonal antibody for moderate to severe asthma, has been associated with arterial thrombotic events. This product is a sub-cutaneous injection and may be self administered, as such local supply arrangements may differ. Prescribers are asked to be vigilant for such events and report these through the Yellow Card system.
Action: Clinicians will find this publication to be a useful review of current issues in drug safety.
|« CKS Update - February 2011||MeReC Extra 48 »|